Research indicated that NOXA/PMAIP1 serves as a marker for an aggressive subtype of pancreatic ductal adenocarcinoma, with NOXA/PMAIP1 expression inducing synthetic lethality upon RUNX1 inhibition in pancreatic cancer (10). The gene discussed is PMAIP1; the disease is pancreatic neoplasm.